Syndevrx: Funding, Investors & Team (Sep 2026)
Syndevrx is a biotech company that specializes in the development of treatments for cancers sensitive to metabolic hormones. Its drugs focus to treat the tumor directly and improve the underlying metabolic hormone dysfunction.
Syndevrx has raised $29.4M across 1 funding round on record, the most recent an undisclosed round of $29.4M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Syndevrx Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Syndevrx Funding Rounds
Syndevrx Founders and Leadership Team
No contact details are on record for this team yet.
Syndevrx Funding Compared to Other Biotechnology Startups
Syndevrx's latest round of $29.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syndevrx in Biotechnology and Cambridge
Companies Similar to Syndevrx
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Syndevrx Funding FAQs
What does Syndevrx do?
Syndevrx is a biotech company that specializes in the development of treatments for cancers sensitive to metabolic hormones. Its drugs focus to treat the tumor directly and improve the underlying metabolic hormone dysfunction.
How much funding has Syndevrx raised?
Syndevrx has raised $29.4M across 1 round on record. The most recent is an undisclosed round of $29.4M announced in Oct 2024.
When did Syndevrx last raise funding?
Syndevrx's most recent funding round on record is an undisclosed round of $29.4M, announced in Oct 2024.
Who founded Syndevrx?
FundedIQ lists James M Shanahan (Founder) at Syndevrx.
Where is Syndevrx headquartered?
Syndevrx is based in Cambridge, Massachusetts, United States.
How many employees does Syndevrx have?
Syndevrx is in the 1-10 employee band.
How does Syndevrx's funding compare to other Biotechnology startups?
Syndevrx's latest round of $29.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Syndevrx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syndevrx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.